Axon Enterprise (formerly TASER) AAXN
Axon is a mature Taser maker masquerading as a SaaS cloud story; aggressive accounting, China-tariff margin pressure, and TAM inflation justify a $27.50-$40 target — 40-60% downside.
Thesis
Axon Enterprises (NASDAQ: AAXN), the rebranded Taser stun-gun maker, is being priced as a high-growth SaaS law-enforcement platform at ~8x sales and 46x EBITDA, but Spruce Point argues the cloud story is a marketing veneer over a mature weapons business. The deck alleges aggressive revenue recognition (hardware booked upfront at zero contract value inflates revenues 6-9%), undisclosed China import exposure that tariffs will compound, an inflated $8.4bn TAM, a botched $17m VIEVU acquisition, a suspicious 3x-sized new HQ, and governance red flags including a former Arthur Andersen partner chairing the audit committee, CFO resignation, insider selling, and Fidelity's exit. Spruce Point models 40%-60% downside to a $27.50-$40 price target versus a $66 stock.
SCQA
Axon, the former TASER, is repositioning from stun-gun hardware into a SaaS cloud platform for body cameras and digital evidence, earning a premium ~8x sales / 46x EBITDA valuation from retail-oriented sell-side analysts.
Aggressive revenue recognition books hardware upfront at zero contract value, inflating sales 6-9%; undisclosed China import reliance will collide with tariffs; TAM is exaggerated; insiders sold $92m while the CFO resigned and Fidelity exited.
Investors should treat Axon as a weapons manufacturer with a small SaaS tail, valuing Taser at 7-9x EBITDA and Software/Sensors at 3.5-5.5x sales — not at SaaS-peer multiples.
Correctly re-rated, Axon is worth $27.56-$40.07 per share versus $66 today, implying 40-60% downside; short sellers capture the gap as accounting, tariff, and TAM disappointments unfold.
The three reasons
- 1
Aggressive revenue recognition: hardware booked upfront at zero contract value inflates revenues 6-9%
- 2
Undisclosed China import dependence plus tariffs will compress gross margins and trigger earnings misses
- 3
Valuation at ~8x sales / 46x EBITDA assumes SaaS upside that TAM, competition, and governance red flags won't deliver
Primary demands
- Investors should sell / avoid AAXN stock given 40%-60% downside risk
- Analysts should revisit bullish models that ignore accounting, tariff, and TAM issues
- Regulators and auditors should scrutinize aggressive revenue recognition and segment cost allocation
KPIs cited
Pattern membership
Precedents cited
- Arthur Andersen / Enron accounting collapse
- Spruce Point's prior exposures of Chinese financial schemes
- Tesla long-term compensation plan (invoked ironically by Axon)
Composition what's on the 72 slides
Slide gallery ·
Notes
Cover slide is a striking body-cam-styled photo of a suspect wearing a 'BUY MY STOCK' shirt being arrested — rare editorial/creative flourish for a short report. Signature Spruce Point tree branding throughout. Argument is broad: accounting, governance, TAM, tariffs, M&A (VIEVU), and valuation are each hit. Peer-valuation table (p.70) and 40-60% downside sum-of-parts (p.72) are the textbook short-seller closers. Arthur Andersen / Enron analogy on p.6 is the playbook move. No stake disclosed (short-seller conventions) but disclaimer confirms Spruce Point and clients are short.